Omalizumab biosimilar is under clinical development by Kashiv BioSciences and currently in Phase I for Asthma. According to GlobalData, Phase I drugs for Asthma have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Omalizumab biosimilar’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Omalizumab biosimilar overview

Omalizumab biosimilar is under development for the treatment of Asthma, chronic idiopathic urticaria. It is developed based on MayaBio reactor technology. The drug candidate is administered through subcutaneous route. It acts by targeting immunoglobulin E.

Kashiv BioSciences overview

Kashiv BioSciences (Kashiv) formerly known as Kashiv Pharma, is a pharmaceutical research company. It develops drug delivery platforms to create improved versions of medicines for patients and physicians. The company also develops innovative technologies, medicines, and life cycle management products. Kashiv provides services such as formulation development, analytical development and clinical supply manufacturing. It also offers contract research and development services to the pharmaceutical sector. Kashiv provides advanced deterrent technologies, formulation and controlled release technologies. The company works in partnership with pharmaceutical companies to commercialize its products. It operates a research and development facility in the US. Kashiv is headquartered in Bridgewater, New Jersey, the US.

For a complete picture of Omalizumab biosimilar’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 22 April 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.